Platelet Factor 4
Domain Structure of Platelet Factor 4
The domain structure of the platelet factor-4 monomer is represented. The platelet factor-4 monomer is a 7,800 molecular weight peptide. The heparin-binding domain is presumably localized within a COOH-terminal region of the molecule where several lysine residues are clustered. In its native state, platelet factor-4 is a homotetramer which exists in complex with a high molecular weight proteoglycan carrier protein.
Price $158.00/100 µg ($144.00/min. 5)
Size 100 µg Formulation 25 mM Hepes, 2 M NaCl, pH 7.4 Storage -80°C Purity >95% by SDS-PAGE Activity Determination Heparin neutralization Shelf Life (properly stored) 12 months
|Load||Human Platelet Factor 4, 1 µg per lane|
|Standard||SeeBluePlus 2; Myosin (191 kDa), Phosphorylase B (97 kDa), BSA (64 kDa), Glutamic Dehydrogenase (51 kDa), Alcohol Dehydrogenase (39 kDa), Carbonic Anhydrase (28 kDa), Myoglobin Red (19 kDa), Lysozyme (14 kDa)|
Platelet factor-4 (PF-4) is a low molecular weight, heparin-binding protein which is secreted from agonist-activated platelets (1,2). PF-4 is localized within the platelet a-granule (2) where its concentration ranges from 11.2-12.4 µg per 109 platelets making it, on a molar basis, one of the most abundant proteins in the platelet (1,2). Since the relative concentration of PF-4 in platelets exceeds that of plasma by 280,000-fold (3), PF-4 levels in plasma have been utilized as a measure of platelet activation in vivo. PF-4 is secreted from platelets in complex with a high molecular weight, proteoglycan, carrier protein (4,5). Sedimentation equilibrium experiments have shown that in the absence of its proteoglycan carrier, the molecular weight of PF-4 is 27,000-29,000 (4,5). Subsequent amino acid sequencing of PF-4 revealed a molecular weight of 7,800 (6-8) indicating that native PF-4 is a homotetramer. Functionally, PF-4 neutralizes the anticoagulant activity of heparin in plasma. The heparin binding site within PF-4 is presumably located within the lysine-rich, COOH-terminal region of the molecule (6-8). Since soluble heparin is a therapeutic agent, the physiological significance of the anti-heparin activity of PF-4 is not known. However, by interacting with cell surface expressed heparin-like glycosaminoglycans on endothelial cells, PF-4 may exert its procoagulant effect (9,10). PF-4 binding to cell surface glycosaminoglycans may also be a mechanism through which PF-4 stimulates the release of histamine from basophils (11). The chemotactic activity of PF-4 toward neutrophils and monocytes (12) has also been localized to the COOH-terminal, presumed heparin-binding domain of PF-4 (13). While PF-4 is primarily a secreted protein, PF-4 binding sites on the platelet surface have been identified which may be important for platelet aggregation (14).
Human PF-4 is prepared from the supernatant of thrombin-activated platelets by heparin-agarose affinity chromatography (15). The purified protein is supplied in 25 mM Hepes pH 7.4, 2 M NaCl and should be stored at -80oC. Purity is assessed by SDS-PAGE analysis and heparin-neutralizing activity is verified by clotting assay.
|Localization||platelet a-granule (2)|
|Mode of action||neutralizes the anticoagulant activity of heparin. Plasma concentration is used as a marker of platelet activation.|
|Molecular weight||29,000 (4)|
|Isoelectric point||7.6 (16)|
|Structure||homotetramer (monomer, Mr~7800) (5-7)|
- Rucinski, B., et al., Blood, 53, 47 (1979).
- Kaplan, K.L., et al., Blood, 53, 604 (1979).
- George, J.N., Blood, 76, 859 (1990).
- Barber, A.G., et al., Biochim. Biophys. Acta, 286, 316 (1972).
- Moore, S., et al., Biochim. Biophys. Acta, 379, 370 (1975).
- Hermodson, M., et al., J. Biol. Chem., 252, 6276 (1977).
- Deuel, T.F., et al., Proc. Natl. Acad. Sci. USA, 74, 2256 (1977).
- Walz, D.A., et al., Thromb. Res., 11, 833 (1977).
- Busch, C., et al., Thromb. Res., 19, 129 (1980).
- Rao, A.K., et al., Blood, 61, 1208 (1983).
- Brindley, L.L., et al., J. Clin. Invest., 72, 1218 (1983).
- Deuel, T.F., et al., Proc. Natl. Acad. Sci. USA, 74, 2256 (1981).
- Osterman, D.G., et al., Biochem. Biophys. Res. Commun., 107, 130 (1982).
- Capitanio, A.M., et al., Biochim. Biophys. Acta, 839, 161 (1985).
- Jordon, R.E., et al., J. Biol. Chem., 257, 400 (1982).
- Niewiarowski, S., and Jameson, B., Human Protein Data (A. Haeberli, ed.) © VCH Verlagsges, mbH, Weinheim
No sample publications.